Home > ALC>
Biography

Dr. Xiaofei Wang

Duke University Medical Center, USA


Email: xiaofei.wang@duke.edu


Qualifications


2003 Ph.D., University of North Carolina

1999 M.Sc., University of North Carolina

1993 M.Sc., Peking University

1990 B.Sc., East China Normal University


Publications (selected)

  1. AT Schroen, GR Petroni, H Wang, M Thielen, R Gray, B Djulbegovic, XF Wang, DJ Sargent, J Benedetti, W Cronin, L Wickerham, A Denicoff, CL Slingluff (2010). Preliminary Evaluation of Factors Associated with Premature Trial Closure and Feasibility of Accrual Benchmarks in Phase III Oncology Trials. Clinical Trials7(4), 312-321; PMID: 20595245.
  2. S Dubey, P J¨anne, L Krug, XF Wang, H Pang, C Watt, J Crawford, R Kratzke, E Vokes, HL Kindler (2010). A phase II study of sorafenib in malignant mesothelioma: Results of CALGB 30307. Journal of Thoracic Oncology 5(10), 1655-1661; PMID: 20736856.
  3. J Salama, TE Stinchcombe, L Gu, XF Wang, J. Bogart, J Crawford, MA Socinski, AW Blackstock, EE Vokes (2011). Pulmonary toxicity in stage III non-small cell lung cancer patients treated with high dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: A secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Int J Radiat Oncol Biol Phys 81(4), e269-274; PMID: 21477940.
  4. GA Masters, XF Wang, L Hodgson, E Vokes, M Green (2011). A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. Lung Cancer 74, 258263; PMID: 21529989.
  5. R Govindan, J Bogart, T Stinchcombe, XFWang, L Hodgson, R Kratzke, J Garst, T Brotherton, E. E. Vokes for the Cancer and Leukemia Group B (2011). A Randomized Phase II Study of Pemetrexed, Carboplatin and Thoracic Radiation with or without Cetuximab in Patients with Locally Advanced Unresectable Nonsmall Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407. Journal of Clinical Oncology 29(23), 3120-3125; PMID: 21747084.
  6. A Kawaguchi, GG Koch, XF Wang (2011). Stratified Multivariate Mann-Whitney Estimators for the Comparison Of Two Treatments with Randomization Based Covariance Adjustment. Statistics in Biopharmaceutical Research 3(2), 217-231.
  7. YG Wu, XF Wang (2011). Optimal Weight in Estimating the Receiver Operating Characteristic Curve Area. Biometrical Journal 53(5), 764-778; PMID: 21805488.
  8. AT Schroen, GR Petroni, H Wang, MT Thielen, DJ Sargent, J Benedetti, W Cronin, L Wickerham, XF Wang, R Gray, W Cohn, CL Slingluff Jr, B Djulbegovic (2011). Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI sponsored trials. Clinical Trials 8(5), 591-600; PMID: 21878447.
  9. MJ Edelman, XF Wang, L Hodgson, R Christenson, E Vokes, R Kratzke (2011). Serum VEGF and COX-2/5LOX Inhibition in Advanced Non-small Cell Lung Cancer: Cancer and Leukemia Group B 150304.Journal of Thoracic Oncology 6(11); 1902-1906; PMID: 21964530.
  10. T Jahan, L Gu, R Kratzke, A Dudek, XF Wang, M Green, E Vokes, H Kindler for the Cancer and Leukemia Group B (2011). Vatalanib (V) in malignant mesothelioma (MM): A phase II study by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer Epub 2011 Dec 22; PMID: 22197613.
  11. J Chen, XF Wang, B Fan (2011). Nonparametric modeling auxiliary covariates in random coefficient models. Communications in Statistics - Simulation and Computation Epub 2011 Oct 5.
  12. MJ Edelman, L Hodgson, PY Rosenblatt, RH Christenson, E Vokes, XF Wang, R Kratzke, for the Cancer and Leukemia Group B (2012). CYFRA 21-1 as a prognostic and predictive marker in advanced non-small cell lung cancer in a prospective trial: CALGB 150304. Journal of Thoracic Oncology 7(4), 649-654.
  13. AT Schroen, GR Petroni, H Wang, MJ Thielen, R Gray, J Benedetti, XF Wang, DJ Sargent, DL Wickerham, W Cronin, B Djulbegovic, CL Slingluff Jr (2012). Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from US Cooperative Oncology Groups. Clinical Cancer Research 18(1), 256-262; PMID: 21976533.